Adding HIPEC to cytoreductive surgery is the main aim of the article, which we have discussed. Cytoreductive surgery has always been a long process with chemotherapy. In this article, we have discussed the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) with the given surgery. There are chances the efficiency of surgery becomes even greater with this addition.

From the year 2008 to the year 2014, more than 265 people came were included, and out of the 133 were given a random addition HIPEC. After a median follow-up of 63·8 months (IQR 53·0–77·1), median overall survival was 41· seven months (95%) in the cytoreductive surgery plus HIPEC group and 41·2 months (35·1–49·7) in the cytoreductive surgery group. So the comparison shows a greater result in the efficiency. After 30 days, Grade 3 events are seen in some cases, but the basics are not disturbed. After 60 days, there were extreme grade 3 events in the added treatment.

After all the above experiments and data, there can be a greater chance of complication when one approaches it with the HIPEC. However, the results are good, but then also it is not a suggested one. The cytoreductive surgery is the main and basic surgery in cases, and it should not be disturbed.